These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31373686)

  • 1. Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types.
    Mathios D; Hwang T; Xia Y; Phallen J; Rui Y; See AP; Maxwell R; Belcaid Z; Casaos J; Burger PC; McDonald KL; Gallia GL; Cope L; Kai M; Brem H; Pardoll DM; Ha P; Green JJ; Velculescu VE; Bettegowda C; Park CK; Lim M
    Int J Cancer; 2019 Dec; 145(12):3425-3435. PubMed ID: 31373686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
    Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
    Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
    Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
    Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.
    Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P
    Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of Novel DNA Methylation-Based Prognostic Model to Predict Survival in Glioblastoma.
    Zhao J; Wang L; Kong D; Hu G; Wei B
    J Comput Biol; 2020 May; 27(5):718-728. PubMed ID: 31460783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome‑wide DNA methylation regulation analysis of long non‑coding RNAs in glioblastoma.
    Ji J; Zhao L; Zhao X; Li Q; An Y; Li L; Li D
    Int J Mol Med; 2020 Jul; 46(1):224-238. PubMed ID: 32319552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis.
    Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D
    J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
    Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
    J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
    Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
    PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide characterization of aberrant DNA methylation patterns and the potential clinical implications in patients with endometrial cancer.
    Wang Y; Liu D; Jin X; Song H; Lou G
    Pathol Res Pract; 2019 Jan; 215(1):137-143. PubMed ID: 30449607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.